<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01287546</url>
  </required_header>
  <id_info>
    <org_study_id>13298</org_study_id>
    <secondary_id>I4C-MC-JTBA</secondary_id>
    <nct_id>NCT01287546</nct_id>
  </id_info>
  <brief_title>A Study of LY2875358 in Participants With Advanced Cancer</brief_title>
  <official_title>A Phase 1 Study of LY2875358 in Patients With Advanced Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Eli Lilly and Company</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Eli Lilly and Company</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective of this study is to determine a recommended Phase 2 dose range of LY2875358&#xD;
      that may be safely administered to participants with advanced cancer. In Part A and Part A2&#xD;
      of this study, escalating doses of LY2875358 as monotherapy and in combination with erlotinib&#xD;
      will be evaluated for safety and tolerability, respectively. Part B is a dose-confirmation&#xD;
      segment for LY2875358 therapy in 5 different types of cancer: nonsquamous non-small cell lung&#xD;
      cancer (NSCLC), castrate resistant prostate cancer (CRPC) with bone metastases, renal cell&#xD;
      carcinoma (RCC), hepatocellular carcinoma (HCC), or uveal melanoma with liver metastases, and&#xD;
      for LY2875358 in combination with trametinib in participants with uveal melanoma with liver&#xD;
      metastases.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Protocol amendment (November, 2013) expanded Part B to study LY2875358 in combination with&#xD;
      trametinib in participants with uveal melanoma with liver metastasis.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">April 13, 2010</start_date>
  <completion_date type="Actual">October 26, 2016</completion_date>
  <primary_completion_date type="Actual">January 8, 2015</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Recommended Phase 2 dose range of LY2875358 monotherapy and in combination with erlotinib</measure>
    <time_frame>Baseline through Cycle 1</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics: Maximum plasma concentration (Cmax)</measure>
    <time_frame>Days 1, 2, 4, 5, 6, 8, 15, and 22 of Cycle 1. Days 1, 15, and 22 of Cycle 2. Days 1 and 15 of Cycles 3 and beyond, as well as 14 days, 29 days, and 57 days following the final treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants with a tumor response</measure>
    <time_frame>Baseline to study completion (12 months)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics: Area under the concentration-time curve (AUC)</measure>
    <time_frame>Days 1, 2, 4, 5, 6, 8, 15, and 22 of Cycle 1. Days 1, 15, and 22 of Cycle 2. Days 1 and 15 of Cycles 3 and beyond, as well as 14 days, 29 days, and 57 days following the final treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to progression and overall survival</measure>
    <time_frame>Baseline to study completion (12 months)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics: Area under the concentration-time curve (AUC) of erlotinib or trametinib in combination with LY2875358</measure>
    <time_frame>Cycle 1</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in Brief Pain Inventory (BPI) in Part B: Expansion Cohort 1</measure>
    <time_frame>Baseline to study completion (12 months)</time_frame>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">117</enrollment>
  <condition>Advanced Cancer</condition>
  <arm_group>
    <arm_group_label>LY2875358</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>LY2875358 + erlotinib</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>LY2875358 at Part A highest dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>LY2875358 at Part A highest dose + trametinib</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>LY2875358</intervention_name>
    <description>Part A Dose escalation of LY2875358 administered intravenously (IV), Day 1 and 15 every 28 days for at least two cycles.</description>
    <arm_group_label>LY2875358</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>LY2875358 + erlotinib</intervention_name>
    <description>Part A2 Dose escalation of LY2875358 administered IV, on Day 1 and 15 every 28 days for at least two cycles in combination with daily erlotinib dosing (150 mg) taken orally (PO).</description>
    <arm_group_label>LY2875358 + erlotinib</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>LY2875358 at Part A highest dose</intervention_name>
    <description>Part B (Dose Exploration): LY2875358 at Part A highest dose administered IV, on Day 1 and 15 every 28 days for at least two cycles.</description>
    <arm_group_label>LY2875358 at Part A highest dose</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>LY2875358 at Part A highest dose + trametinib</intervention_name>
    <description>Part B (in combination with trametinib): LY2875358 at Part A highest dose administered IV, on Day 1 and 15 every 28 days for at least two cycles, in combination with trametinib at 2 mg orally once daily</description>
    <arm_group_label>LY2875358 at Part A highest dose + trametinib</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Part A: Have histological or cytological evidence of cancer (solid tumor, lymphoma, or&#xD;
             multiple myeloma) that is advanced and/or metastatic and an appropriate candidate for&#xD;
             experimental therapy&#xD;
&#xD;
          -  Part A2: Histologic or cytologic diagnosis of advanced Non Small Cell Lung Cancer&#xD;
             (NSCLC), Stage IIIB with malignant pleural effusion or Stage IV, completed at least 1&#xD;
             prior systemic regimen, and eligible for erlotinib therapy.&#xD;
&#xD;
          -  Part B: Candidate for experimental therapy after standard therapies used or&#xD;
             non-eligible for standard therapies. Histological or cytological evidence of 1 of the&#xD;
             5 tumor types:&#xD;
&#xD;
          -  Castrate-resistant prostate cancer (CRPC) with bone metastasis:&#xD;
&#xD;
             --Progressive Disease in the setting of castrate level of testosterone&#xD;
&#xD;
          -  Renal Cell Carcinoma (RCC):&#xD;
&#xD;
             --Histologic diagnosis of either clear-cell or papillary RCC (metastatic and&#xD;
             unresectable, or bilateral, multifocal, unresectable RCC localized to kidneys).&#xD;
&#xD;
          -  NSCLC:&#xD;
&#xD;
             --Histologic or cytologic diagnosis of advanced NSCLC, Stage IIIB with malignant&#xD;
             pleural effusion or Stage IV&#xD;
&#xD;
          -  Hepatocellular Carcinoma (HCC)&#xD;
&#xD;
             --Histologic or cytologic diagnosis of hepatocellular carcinoma&#xD;
&#xD;
          -  Uveal Melanoma with liver metastasis&#xD;
&#xD;
          -  Part A: Have the presence of measurable or nonmeasurable disease as defined by the&#xD;
             RECIST v1.1 (Eisenhauer et al. 2009) or Revised Response Criteria for Malignant&#xD;
             Lymphoma (Cheson et al. 2007) or have measureable disease for multiple myeloma.&#xD;
&#xD;
          -  Part A2 &amp; B (RCC, NSCLC, HCC, and uveal melanoma): Have measurable disease as defined&#xD;
             by RECIST v1.1.&#xD;
&#xD;
          -  Give written informed consent prior to any study-specific procedures.&#xD;
&#xD;
          -  Adequate organ function.&#xD;
&#xD;
          -  Performance status of less than or equal to 2 on ECOG scale.&#xD;
&#xD;
          -  Discontinued all previous cancer therapies, and any agents that have not received&#xD;
             regulatory approval, for at least 21 days and recovered from the acute effects of&#xD;
             therapy. Must have discontinued mitomycin-C or nitrosourea therapy for at least 42&#xD;
             days.&#xD;
&#xD;
          -  Reliable and available for the duration of the study and willing to follow study&#xD;
             procedures.&#xD;
&#xD;
          -  Males and females (reproductive potential): Use medically approved contraceptive&#xD;
             precautions during the study and for 4 months following the last dose of study drug.&#xD;
&#xD;
          -  Females (childbearing potential): Have had a negative serum pregnancy test before the&#xD;
             first dose of study drug and not be breast-feeding.&#xD;
&#xD;
          -  Estimated life expectancy that will permit the participants to complete 8 weeks of&#xD;
             treatment.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Serious preexisting medical conditions&#xD;
&#xD;
          -  Symptomatic central nervous system malignancy or metastasis (screening not required).&#xD;
&#xD;
          -  Acute or chronic leukemia.&#xD;
&#xD;
          -  Active infection including HIV, hepatitis A, B or C&#xD;
&#xD;
          -  Have second primary malignancy that may affect the interpretation of results.&#xD;
&#xD;
          -  Have received a liver transplant, or have liver cirrhosis with a Child-Pugh Stage of B&#xD;
             or C.&#xD;
&#xD;
          -  Patients with active alcohol abuse, as determined by the treating investigator.&#xD;
&#xD;
          -  Part A2: Unable to swallow tablets. Intolerant of therapy with erlotinib. Concomitant&#xD;
             treatment with the cytochrome P450 3A (CYP3A) modulators. Must not have received&#xD;
             treatment with any of these modulators within 14 days of study treatment.&#xD;
&#xD;
          -  Have a history of New York Heart Association class ≥3, unstable angina, myocardial&#xD;
             infarction 6 months prior to study drug&#xD;
&#xD;
          -  QTc greater than 470 msec.&#xD;
&#xD;
          -  Received previous treatment with any c-MET experimental therapeutic.&#xD;
&#xD;
          -  Part B Expansion Cohort 1 (CRPC):&#xD;
&#xD;
               1. Increasing use of daily doses of opioid analgesics within 28 days prior to&#xD;
                  enrollment in the study.&#xD;
&#xD;
               2. Neuroendocrine prostate cancer.&#xD;
&#xD;
               3. Patients who have a solitary bone metastasis that has been irradiated are not&#xD;
                  eligible.&#xD;
&#xD;
          -  Part B Expansion Cohort 6 (LY2875358 plus trametinib in participants with uveal&#xD;
             melanoma with liver metastasis): Contra-indications for trametinib&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)</last_name>
    <role>Study Director</role>
    <affiliation>Eli Lilly and Company</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of California - San Diego</name>
      <address>
        <city>La Jolla</city>
        <state>California</state>
        <zip>92037-0845</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cedars Sinai Medical Center</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90048-5615</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Univ of California San Francisco</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94115</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UCLA</name>
      <address>
        <city>Santa Monica</city>
        <state>California</state>
        <zip>90404</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mayo Clinic of Jacksonville</name>
      <address>
        <city>Jacksonville</city>
        <state>Florida</state>
        <zip>32224</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Emory University</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30322</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Massachusetts General Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02114</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Michigan</name>
      <address>
        <city>Ann Arbor</city>
        <state>Michigan</state>
        <zip>48109-0946</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mayo Clinic</name>
      <address>
        <city>Rochester</city>
        <state>Minnesota</state>
        <zip>55902</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Thomas Jefferson University</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19107</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2017</verification_date>
  <study_first_submitted>January 28, 2011</study_first_submitted>
  <study_first_submitted_qc>January 31, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 1, 2011</study_first_posted>
  <last_update_submitted>February 14, 2017</last_update_submitted>
  <last_update_submitted_qc>February 14, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">February 15, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Erlotinib Hydrochloride</mesh_term>
    <mesh_term>Trametinib</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

